Journal of International Oncology
  • Home
  • About Journal
    • About Journal
    • Journal History
    • Objective
  • Editorial Committee
    • Editorial Boards
    • Communications Editorial Board
    • Introduction to Editor-in-Chief
    • General Principles of the Editorial Board
  • Guide for Authors
    • Online Submission Guide
    • Instructions for Authors
  • Publication Ethics
  • Aim and Scope
  • Subscribe
  • Contacts Us
  • 中文

Journal of International Oncology››2016,Vol. 43››Issue (11): 877-878.doi:10.3760/cma.j.issn.1673-422X.2016.11.021

Previous ArticlesNext Articles

    • Received:2016-03-21Online:2016-11-08Published:2016-11-02

    PDF

    1206

    Knowledge

    0

    Abstract

    Cite this article

    share this article

    /Recommend

    Add to citation managerEndNote|Reference Manager|ProCite|BibTeX|RefWorks

    URL:https://gjzlx.sdfmu.edu.cn/EN/10.3760/cma.j.issn.1673-422X.2016.11.021

    https://gjzlx.sdfmu.edu.cn/EN/Y2016/V43/I11/877

    References

    [1] AlvaradoLuna G, MoralesEspinosa D. Treatment for small cell lung cancer, where are we now?—a review[J]. Transl Lung Cancer Res, 2016, 5(1): 26-38. DOI: 10.3978/j.issn.22186751.2016.01.13. [2] Califano R, Abidin AZ, Peck R, et al. Management of small cell lung cancer: recent developments for optimal care[J]. Drugs, 2012, 72(4): 471-490. DOI: 10.2165/11597640-000000000-00000. [3] Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years[J]. Transl Lung Cancer Res, 2016, 5(1): 39-50. DOI: 10.3978/j.issn.22186751.2016.01.03. [4] Sgambato A, Casaluce F, Maione P, et al. Medical treatment of small cell lung cancer: state of the art and new development[J]. Expert Opin Pharmacother, 2013, 14(15): 2019-2031. DOI: 10.1517/14656566.2013.823401. [5] Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive smallcell lung cancer[J]. N Engl J Med, 2002, 346(2): 85-91. [6] Hanna N, Bunn PA, Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensivestage disease smallcell lung cancer[J]. J Clin Oncol, 2006, 24(13): 2038-2043. DOI: 10.1200/JCO.2005.04.8595. [7] Schmittel A, Sebastian M, Fischer Von Weikersthal L, et al. A German multicenter, randomized phase Ⅲ trial comparing irinotecancarboplatin with etoposidecarboplatin as firstline therapy for extensivedisease smallcell lung cancer[J]. Ann Oncol, 2011, 22(8): 17981804. DOI: 10.1093/annonc/mdq652. [8] Slotman BJ, Van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage smallcell lung cancer: a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962): 36-42. DOI: 10.1016/S0140-6736(14)61085-0. [9] Rossi A, Sacco PC, Sgambato A, et al. Optimal drugs for secondline treatment of patients with smallcell lung cancer[J]. Expert Opin Pharmacother, 2016, 17(7): 969-976. DOI: 10.1517/14656566.2016.1154539. [10] Reck M, Heigener D, Reinmuth N. Immunotherapy for smallcell lung cancer: emerging evidence[J]. Future Oncol, 2016, 12(7): 931-943. DOI: 10.2217/fon-2015-0012.

    Related Articles0

    No related articles found!

    Recommended Articles

    Metrics

    Viewed
    Full text


    Abstract

    Comments

    • Abstract
    • References
    • Related Articles
    • Recommended Articles
    • Metrics
    • Comments
    TOP


    Copyright © Editorial office of Journal of International Oncology
    Tel: 0531-59556327 59556328 
    E-mail: gjzlxjn@126.com